S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE! (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE! (Ad)
Corruption scandals cast a shadow over Portugal’s early general election and may favor populists
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE! (Ad)
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
AT&T will give $5 to customers hit by cellphone network outage
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE! (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE! (Ad)
Corruption scandals cast a shadow over Portugal’s early general election and may favor populists
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE! (Ad)
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
AT&T will give $5 to customers hit by cellphone network outage
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE! (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE! (Ad)
Corruption scandals cast a shadow over Portugal’s early general election and may favor populists
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE! (Ad)
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
AT&T will give $5 to customers hit by cellphone network outage
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE! (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE! (Ad)
Corruption scandals cast a shadow over Portugal’s early general election and may favor populists
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE! (Ad)
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
AT&T will give $5 to customers hit by cellphone network outage

AzurRx BioPharma (AZRX) Competitors

Notice: This company has been marked as potentially delisted and may not be actively trading.

AZRX vs. FIXX, IPA, AADI, CKPT, MIST, BYSI, SCTL, BIVI, ELDN, and NXTC

Should you be buying AzurRx BioPharma stock or one of its competitors? The main competitors of AzurRx BioPharma include Homology Medicines (FIXX), ImmunoPrecise Antibodies (IPA), Aadi Bioscience (AADI), Checkpoint Therapeutics (CKPT), Milestone Pharmaceuticals (MIST), BeyondSpring (BYSI), Societal CDMO (SCTL), BioVie (BIVI), Eledon Pharmaceuticals (ELDN), and NextCure (NXTC). These companies are all part of the "medical" sector.

AzurRx BioPharma vs.

Homology Medicines (NASDAQ:FIXX) and AzurRx BioPharma (NASDAQ:AZRX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability, community ranking and analyst recommendations.

Homology Medicines has higher revenue and earnings than AzurRx BioPharma. AzurRx BioPharma is trading at a lower price-to-earnings ratio than Homology Medicines, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Homology Medicines$3.21M15.53-$5.01M-$2.28-0.38
AzurRx BioPharmaN/AN/A-$32.67M-$11.50-0.51

AzurRx BioPharma received 100 more outperform votes than Homology Medicines when rated by MarketBeat users. Likewise, 74.26% of users gave AzurRx BioPharma an outperform vote while only 64.43% of users gave Homology Medicines an outperform vote.

CompanyUnderperformOutperform
Homology MedicinesOutperform Votes
125
64.43%
Underperform Votes
69
35.57%
AzurRx BioPharmaOutperform Votes
225
74.26%
Underperform Votes
78
25.74%

In the previous week, AzurRx BioPharma's average media sentiment score of 0.00 equaled Homology Medicines'average media sentiment score.

Company Overall Sentiment
Homology Medicines Neutral
AzurRx BioPharma Neutral

AzurRx BioPharma has a net margin of 0.00% compared to AzurRx BioPharma's net margin of -4,779.31%. AzurRx BioPharma's return on equity of -97.60% beat Homology Medicines' return on equity.

Company Net Margins Return on Equity Return on Assets
Homology Medicines-4,779.31% -97.60% -71.29%
AzurRx BioPharma N/A -482.96%-258.47%

30.0% of Homology Medicines shares are held by institutional investors. Comparatively, 6.3% of AzurRx BioPharma shares are held by institutional investors. 16.1% of Homology Medicines shares are held by insiders. Comparatively, 7.3% of AzurRx BioPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Homology Medicines has a beta of -0.15, suggesting that its stock price is 115% less volatile than the S&P 500. Comparatively, AzurRx BioPharma has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500.

Homology Medicines presently has a consensus target price of $9.50, suggesting a potential upside of 1,001.96%. Given AzurRx BioPharma's higher probable upside, equities analysts clearly believe Homology Medicines is more favorable than AzurRx BioPharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Homology Medicines
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
AzurRx BioPharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Summary

Homology Medicines beats AzurRx BioPharma on 10 of the 14 factors compared between the two stocks.


Get AzurRx BioPharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for AZRX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AZRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AZRX vs. The Competition

MetricAzurRx BioPharmaPharmaceutical Preparations IndustryMedical SectorNASDAQ Exchange
Market Cap$54.65M$6.89B$5.16B$7.54B
Dividend YieldN/A2.78%2.87%3.86%
P/E Ratio-0.5411.64194.0016.57
Price / SalesN/A254.313,073.4369.93
Price / CashN/A18.1899.5754.97
Price / Book-7.714.674.414.60
Net Income-$32.67M$160.62M$114.48M$207.21M

AzurRx BioPharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FIXX
Homology Medicines
4.1055 of 5 stars
$0.82
+2.5%
$9.50
+1,053.1%
-38.0%$47.63M$3.21M-0.3692
IPA
ImmunoPrecise Antibodies
1.9059 of 5 stars
$1.86
-5.6%
$8.00
+330.1%
-55.5%$48.96M$15.61M-3.96102
AADI
Aadi Bioscience
1.5622 of 5 stars
$1.91
+0.5%
$24.67
+1,191.4%
-82.3%$46.85M$15.22M-0.8188News Coverage
CKPT
Checkpoint Therapeutics
3.8861 of 5 stars
$1.98
-1.5%
$22.60
+1,041.4%
-54.9%$46.59M$190,000.000.0024News Coverage
MIST
Milestone Pharmaceuticals
2.3361 of 5 stars
$1.50
-2.0%
$12.75
+750.0%
-45.9%$50.22M$5M-1.0939
BYSI
BeyondSpring
0.0605 of 5 stars
$1.18
-11.3%
$1.25
+5.9%
-42.6%$45.93M$1.35M0.0073News Coverage
SCTL
Societal CDMO
1.937 of 5 stars
$0.49
-2.0%
$1.88
+282.7%
-65.0%$51.35M$91.20M-1.63275Gap Up
BIVI
BioVie
2.4077 of 5 stars
$1.12
-8.9%
$8.00
+614.3%
-81.3%$44.65MN/A-0.9618News Coverage
ELDN
Eledon Pharmaceuticals
2.6855 of 5 stars
$1.84
+0.5%
$10.67
+479.7%
-18.6%$44.53MN/A-0.3317Gap Up
NXTC
NextCure
4.2351 of 5 stars
$1.57
+7.5%
$5.50
+250.3%
-7.5%$43.80MN/A-0.6799Positive News
Gap Down
High Trading Volume

Related Companies and Tools

This page (NASDAQ:AZRX) was last updated on 2/25/2024 by MarketBeat.com Staff